NASDAQ
26.06.26 | 21:59
4,060 US-Dollar
+0,50 % +0,020
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ZENTALIS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 18.06. | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 01.06. | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 22.05. | H.C. Wainwright reiterates Zentalis stock rating on ovarian cancer data | 1 | Investing.com | ||
| 22.05. | H.C. Wainwright bestätigt Kaufempfehlung für Zentalis nach Daten zu Eierstockkrebs | 1 | Investing.com Deutsch | ||
| 22.05. | Zentalis to present ovarian cancer trial data at ASCO meeting | 2 | Investing.com | ||
| 21.05. | Zentalis präsentiert auf Jährlicher ASCO-Tagung Studiendaten zu Eierstockkrebs | - | Investing.com Deutsch | ||
| 21.05. | Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026 | 2 | GlobeNewswire (USA) | ||
| 21.05. | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 12.05. | Zentalis Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.05. | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 05.05. | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 01.05. | Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 21.04. | Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer | 2 | GlobeNewswire (USA) | ||
| 17.04. | Zentalis präsentiert Daten zu Krebsmedikament Azenosertib - Aktie unter Druck | 2 | Investing.com Deutsch | ||
| 17.04. | Zentalis presents preclinical data on cancer drug azenosertib | 10 | Investing.com | ||
| 17.04. | Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026 | 1 | GlobeNewswire (USA) | ||
| 17.04. | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 10.04. | Jefferies raises Zentalis stock price target on ovarian cancer trial data | 5 | Investing.com | ||
| 10.04. | Guggenheim erhöht Kursziel für Zentalis-Aktie nach positiven Daten zu Krebsmedikament | 7 | Investing.com Deutsch | ||
| 10.04. | Guggenheim raises Zentalis stock price target on ovarian cancer drug data | 1 | Investing.com |
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MODERNA | 57,96 | -1,91 % | Bayer und PORR werden für Produktionsanlage ausgezeichnet | ||
| VALNEVA | 2,265 | -0,04 % | VALNEVA SE: Valneva Announces Successful Outcome of its Annual General Meeting | Dr. Gerd Zettlmeissl is appointed as Chair of the Board of Directors Lyon (France), June 25, 2026 - Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that... ► Artikel lesen | |
| NOVAVAX | 7,750 | -0,77 % | Novavax faces renewed attack by Shah Capital after AGM | ||
| VIVOSIM LABS | 1,030 | 0,00 % | VivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales | SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,030 | 0,00 % | Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update | Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update
Compelling kidney function data and meta-analysis from two Phase 2 studies with varoglutamstat presented... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,349 | -3,86 % | NurExone bringt Entwicklung, Finanzierung und US-Ausbau voran | ||
| SAREPTA THERAPEUTICS | 14,660 | -1,08 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| VAXART | 0,380 | 0,00 % | Vaxart, Inc. - 8-K, Current Report | ||
| IMMUNITYBIO | 7,590 | 0,00 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| XOMA ROYALTY | 37,400 | +0,54 % | XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date | EMERYVILLE, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) ("XOMA" or the "Company") today announced that its Board of Directors has authorized the following cash... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,067 | -3,18 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update | Completed successful End-of-Phase 2 meeting with the FDA and selected onvansertib dose and chemotherapy regimen for planned Phase 3 trial Company to provide detailed data update from Phase 2 CRDF-004... ► Artikel lesen | |
| ALDEYRA | 1,510 | -6,79 % | Aldeyra appoints Darlene Deptula-Hicks to board of directors | ||
| IOVANCE BIOTHERAPEUTICS | 3,740 | +0,54 % | Iovance Biotherapeutics, Inc.: Iovance's Amtagvi (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia | First T cell therapy for a solid tumor cancer and first treatment option approved in Australia for advanced melanoma after anti-PD-1 and targeted therapy SAN CARLOS, Calif., June 03, 2026 (GLOBE... ► Artikel lesen | |
| GUARDANT HEALTH | 129,74 | -1,08 % | Bernstein upgrades Guardant Health stock rating on FDA approval impact | ||
| TRAWS PHARMA | 0,840 | +1,57 % | Traws Pharma, Inc.: Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program | NEWTOWN, Pa., June 22, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, Traws, the Company), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral... ► Artikel lesen |
ZENTALIS PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +0,50 % bei einem Aktienkurs von 4,060 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZENTALIS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.